• Sign Up

Peripheral T-Cell Lymphoma


Peripheral T-Cell Lymphoma

Article Author:
Hussain Rangoonwala
Article Editor:
Marco Cascella
Updated:
8/27/2020 10:45:53 AM
For CME on this topic:
Peripheral T-Cell Lymphoma CME
PubMed Link:
Peripheral T-Cell Lymphoma

Introduction

Peripheral T cell lymphoma (PTCL) is a heterogeneous group of lymphomas accounting for 5% to 15% of non-Hodgkin lymphomas (NHL), in the western world. It is comprised of peripheral (systemic) and cutaneous forms developed from T-cells and natural killer (NK) cells. Clinically, these lymphomas are often aggressive.[1][2][3]

Angioimmunoblastic T cell lymphoma (AITL) is nowadays considered a separate subtype of PTCL. This form, described in 1974 by Frizzera et al., was previously known by several synonyms such as 'angioimmunoblastic lymphadenopathy with dysproteinemia', 'immunoblastic lymphadenopathy', and 'lymphogranulomatosis X'.[4] The follicular T helper cell, based on molecular analyses, is considered the cell of origin for AITL.[4][5][6][1]

Cutaneous lymphomas are NHLs manifesting in the skin in the absence of extracutaneous manifestations at the time of diagnosis. Further subdivided into cutaneous B-cell lymphoma (CBCL) and cutaneous T-cell lymphoma (CTCL), CTCLs comprise up to four-fifths of all primary cutaneous lymphomas. Of note, CTCLs are classified separately from the group of PTCLs.

Among the CTCLs there are Mycosis fungoides (MF), Primary cutaneous anaplastic large cell lymphoma, and Sezary syndrome (SS). MF also termed 'Alibert-Bazin syndrome' or 'granuloma fungoides', represents the most common type of CTCL while remaining a rare type of NHL. Primary cutaneous anaplastic large cell lymphoma is another form of CTCL. Both contribute to roughly four-fifths of all CTCLs.

Large Cell Cutaneous Ki-1 Anaplastic Lymphoma also termed as 'Anaplastic large cell lymphoma' (ALCL) or 'CD30 positive anaplastic large cell lymphoma' is a rare and aggressive type of PTCL (NHL). This form is encompassed among the group of CD30-positive lymphoproliferative disorders and can affect lymph nodes and extranodal sites. Usually, based on the expression of the anaplastic lymphoma kinase (ALK) protein, two sub-types are described: ALK-positive and ALK-negative Large Cell Cutaneous Ki-1 Anaplastic Lymphoma.

SS is a rare leukemic form of CTCL. It is historically identified as a triad of pruritic erythroderma, generalized lymphadenopathy, and the presence of distinct “Sezary cells” in the skin, lymph nodes, and peripheral blood. Although MF is a primary subtype of CTCL, it has historically and inappropriately been used interchangeably with CTCL.[7][8] It is an aggressive form of CTCL.

This chapter will address:

  • Angioimmunoblastic T cell lymphoma
  • Large Cell Cutaneous Ki-1 Anaplastic Lymphoma
  • Cutaneous T-cell lymphoma:
    • Mycosis fungoides
    • Sezary syndrome

Etiology

A pooled analysis from 15 case-control studies identified the following risk factors as associated with a high overall statistically significant risk of developing PTCL, including a family history of hematologic malignancies, eczema, psoriasis, celiac disease, heavy smoking, certain occupations (textile worker, electrical fitter).[9] 

The etiology of the Large Cell Cutaneous Ki-1 Anaplastic Lymphoma is unknown. Molecular investigation proved that in the ALK-positive sub-type, the tyrosine kinase receptor ALK gene (2p23) is overexpressed due to a t(2;5)(p23;q35) translocation.[10]

The etiological picture of MS and SS is uncertain. Environmental factors, immunological alterations, infections, and other tumors are possible factors that could favor the onset of CTCLs. Considering that subjects affected by these pathologies have a familial predisposition to tumors, it seems that genetic factors are more involved in the onset of MF and SS than other lymphomas.

Epidemiology

AITL comprises up to 2% of all NHL cases; however, it represents one out of every five PTCL cases per annum. After PTCL not otherwise specified (NOS), it is considered the most common PTCL subtype. It carries a 1:1 male to female ratio, is more common in Europe than in Asia or North America, and has a median age of 65-70 yrs. in the United States (US) and worldwide.[3][11][12] 

Retrospective studies showed that the incidence of CTCL increased steadily between 1973 and 1998 and has stabilized since then. Moreover, CTCL incidence is twice in males compared to females. It is common in African Americans, metropolitan areas, and patients with higher income and education levels. Increased incidence was observed in patients following organ transplants and those with HIV.[13][14][15][16]

MF, the commonest CTCL subtype, comprise about 50% of all CTCLs. The incidence rate is almost twice as common in males with a median age at diagnosis between 55 and 60. Hispanic patients were observed to present at younger ages, higher stage, and aggressive clinical course. Sezary syndrome represents about 3-5% of all CTCLs and is more common in non-Hispanic whites.[17][18][19][20][21] 

Large cell cutaneous Ki-1 anaplastic lymphoma represents about 25% to 30% of all CTCLs and is the second most common subtype after MF. It is seen most among non-Hispanic whites and has an excellent prognosis. It can occur at any age with a peak incidence in the 60s.[14][22][23]

History and Physical

Common clinical features of AITL includes B-symptoms (drenching night sweats, fever, weight loss) and lymphadenopathy. Enlargement of the liver and spleen may be present at diagnosis. Rashes may be the antecedent finding in about 20% to 50% of AITL patients, with skin manifestations ranging from urticarial lesions to nodular tumors.[24][25][26]

Patients with CTCLs often present with “chronic dermatitis,” that is resistant to therapy and often misdiagnosed as chronic nonspecific dermatoses. The lesions of MF may progress from “patch” to “plaque” to “tumor.” A patch is a flat lesion with varying degrees of erythroderma, and plaque is a raised, well-demarcated lesion less than a cm in size. In contrast, the tumor is defined as a raised lesion greater than a centimeter. The clinical-stage determines the distribution of lesions with early-stage having a predilection for folds and non-exposed sun areas.

Lesions are usually pruritic, with severity known for determining the quality of life in these patients. Sezary syndrome, the aggressive leukemic form of CTCLs, is characterized by pruritic erythroderma, generalized lymphadenopathy, and circulating leukemic “Sezary cells” in the peripheral blood. PCALCL usually presents as a brownish to violaceous nodule or tumor and may be solitary to generalized in distribution.[27][28]

Evaluation

Angioimmunoblastic T cell lymphoma

Initial evaluation, in addition to physical examination, should include complete blood count, comprehensive metabolic panel, LDH, HTLV-1, systemic imaging such as CT chest, abdomen, pelvis with contrast, or positron emission tomographic [PET-CT] scan, bone marrow evaluation, echocardiogram (before anthracycline therapy).[1] 

Diagnosis is based on clinical features, histopathologic features, immunophenotyping, and molecular studies. 

Hematology

Some of the hematological abnormalities include polyclonal hypergammaglobulinemia, direct coombs positive autoimmune hemolytic anemia, peripheral eosinophilia.[12] 

Histopathology

The cell of origin of AITL is the follicular T helper cell. There is dysregulation of T helper cells resulting in unchecked B cell activation and development of AITL. It is histologically characterized by effacement of normal lymphoid architecture, accompanied by a pleomorphic cellular infiltrate, resulting in loss of follicles and extensive intranodal revascularization. The cellular infiltrate includes B cells, plasma cells, histiocytes, eosinophils. Some of the B cells are EBV+ reflecting the immunodeficient state.[12][6][29]

Immunophenotyping and molecular studies

Immunophenotyping reveals that the malignant cells are CD3+, CD4+, and CD10+. CXCL13, uniformly expressed in neoplastic cells, is diagnostically significant, whereas CD30+, which is seen in about 20% of all AITLs, is therapeutically relevant.[30][31][32]

An abnormal karyotype is seen in AITL and frequently involves chromosomes 3 and 5. Clonal complexity is considered a negative prognostic factor.[33][34] 

A diagnosis of diffuse large B-cell lymphoma may be uncovered concomitantly at the time of diagnosis of AITL or at relapse, warranting the need for re-biopsy if a relapse is suspected. 

Large Cell Cutaneous Ki-1 Anaplastic Lymphoma

The diagnosis depends on clinical and histopathological findings. Histopathology usually reveals large cells, with about 75% expressing CD30. Immunophenotyping reveals that mostly these cells are CD4+ with loss of pan-T markers such as CD2, CD3, and CD 5. In contrast to systemic ALCL, the cells in PCALCL are usually negative for CD15 and epithelial membrane antigen.[35]

Mycosis fungoides and Sezary Syndrome

Diagnosis is usually based on clinical and histopathologic findings. Once a diagnosis is made, accurate staging is essential as it provides prognostic significance. Initial workup includes biopsy of the skin and/or lymph nodes, bone marrow biopsy (if cytopenia or extracutaneous disease is suspected), flow cytometry, and systemic imaging. The purpose of flow cytometry is to assess the clonality of T-cells. 

Histopathology: The classic MF skin lesion appears as a superficial lichenoid lymphocytic infiltrate. The lymphocytes range from small to large and characteristically reveal cerebriform nuclei. The hallmark of this malignant infiltrate is epidermotropism (lymphocytes frequent the epidermis without any obvious spongiosis) and clusters of lymphocytes around the Langerhans cell in the epidermis, what is known as the Pautrier microabscesses. In the advanced stages, there is a lack of epidermotropism, and the lymphocytes are characteristically large, atypical, and extend deeper into the dermis.[36]

Immunophenotyping plays a vital role in diagnosis, with cells expressing CD3+CD4+CD45RO+CD8-. Loss of maturation markers on the CD4+ cell, such as CD7 and CD26, indicates malignant clonality of the T-lymphocyte.[37]

Treatment / Management

Angioimmunoblastic T cell Lymphoma 

General approach:

Despite the seemingly disappointing failure-free survival rates, CHOP (cyclophosphamide, daunorubicin, vincristine, prednisone) therapy is the most employed backbone in the upfront setting based on data from three large retrospective studies. CHOP for six cycles every three weeks is considered the standard therapy for patients newly diagnosed with AITL over the age of 60. A recent double-blind, placebo-controlled randomized clinical trial comparing brentuximab vedotin plus CHP (cyclophosphamide, hydroxydaunorubicin, prednisone) versus CHOP for CD30+ peripheral T-cell lymphomas, revealed significantly better progression-free survival and overall survival with the former. CHOP with etoposide (CHOEP) was seen to improve event-free survival in a cohort consisting of AITL patients, but this was statistically insignificant. CHOEP may provide the ability to achieve deeper remission, which would ensure that the patient receives a transplant. Nonrandomized data supports the use of High dose therapy and autologous stem cell transplantation in the upfront setting.[1][12][38][39][40][41]

Treatment of relapsed/refractory AITL 

Management of relapsed/refractory (primary progressive) AITL is currently evolving. If patients are eligible for transplant and have not received it during initial treatment, divergent treatment patterns have evolved. These include short course combination regimens borrowed from relapsed, aggressive B-cell lymphomas such as ICE (ifosfamide, carboplatin, etoposide) and DHAP (dexamethasone, cisplatin, cytarabine) with an overall response rate (ORR) of up to 70%, and the other is continuous therapy which includes the Histone Deacetylase (HDAC) inhibitors such as romidepsin and belinostat. The overall response rate to romidepsin was 30%, whereas belinostat had an ORR of 45% in AITL. For patients who are “transplant-ineligible” with relapsed/refractory AITL, median OS is 5.5 months, and continuous therapy, as mentioned above, are options.[12] 

Large Cell Cutaneous Ki-1 Anaplastic Lymphoma

Anthracycline-based chemotherapy, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimen, is the treatment of the first choice. This approach can be combined with radiotherapy in stage I/II disease. Pediatric patients follow different protocols, similar to those used for B-cell lymphomas, and in combination with other drugs such as methotrexate, etoposide, and cytarabine. Also, high-dose chemotherapy, followed by autologous stem cell transplantation, may be offered, usually in the case of relapses or as a first-choice treatment in the case of a poor prognosis. Conjugated antibodies (brentuximab vedotin) may be given when at least one chemotherapy protocol has proved ineffective.

Mycosis fungoides and Sezary Syndrome

Management of MF and SS is heavily reliant on the accurate staging of this condition. Staging of MF and SS is essential for choosing therapy and for prognostication. It is unique as it incorporates atypical circulating cells in the blood (B) and tumor, nodes, and metastases (TNMB classification).

Staging

Tumor or “T” is further classified into four types and classified based on the appearance of skin lesions. T1 means limited patches/papules/plaques involving less than 10% skin area, T2 describes generalized patches/papules/plaques involving greater than 10% of skin area, T3 is any tumor greater than or equal to 1 cm in size, and T4 is generalized erythroderma over at least 80% of surface area. Nodes (N) are classified based on clinical examination and histopathological grade of lymph nodes (LN). N0 means no clinically abnormal appearing LN. N1 is abnormal appearing lymph node in addition to histopathological Dutch grade 1 or NCI grade 0 to 2, N2 is abnormal LN in addition to Dutch grade 2/NCI grade 3, and N3 is abnormal LN in addition to Dutch grade 3 to 4/NCI grade 4. Metastases or “M” are classified based on visceral involvement, with M0, which means no visceral involvement and M1, which implies visceral organ involvement. Blood or “B” is subdivided into B0, B1, and B2. B0 is circulating atypical cells (Sezary cells) less than 5%, B1 is defined as Sezary cells greater than 5%. B2 is defined as Sezary cells greater than 1000 cells/mm3, CD4/CD8 ratio higher than 10, and evidence of a T cell clone.[42]

Based on the revised staging by ISCL/EORTC in 2007, blood involvement (B) is incorporated into the clinical staging. Stage I is determined mainly by skin involvement (T) and is divided into IA (T1 N0 M0 B0/1) and IB (T2 N0 M0 B0/1). Stage II is determined mainly by skin involvement (T) and nodal involvement; it is subdivided into IIA (T1/2 N1/2 M0 B0/1) and IIB (T3 N1/2 M0 B0/1). Stage III is characterized by erythroderma (T4) and is subdivided into IIIA (T4 N0-2 M0 B0) and IIIB (T4 No-2 M0 B1). Stage IV is determined by blood involvement and metastases; it is subdivided into IVA1 (T1-4 N0-2 M0 B2), IVA2 (T1-4 N3 M0 B0-2), and IVB (T1-4 N0-3 M1 B0-2).[42]

Treatment approach

Treatment approaches for MF and SS involve local and systemic therapy. Local therapy or skin-directed therapy includes topical glucocorticoids, topical nitrogen mustard, topical tacrolimus, topical carmustine, topical retinoids, imiquimod, phototherapy, photodynamic therapy, and electron beam therapy. Options for systemic therapy includes oral retinoids, histone deacetylase inhibitors (vorinostat, romidepsin), interferon-alpha, extracorporeal photopheresis, monoclonal antibodies (anti CD52, alemtuzumab), monoclonal antibody conjugate (anti CD30 therapy, brentuximab vedotin), chemotherapy.

Local therapy

The general treatment philosophy is that skin-directed therapy is used in early stages (IA and IB) or combination with systemic agents in advanced disease. Topical glucocorticoids are rarely used as monotherapy, and they have the disadvantage of causing skin atrophy. Topical carmustine, tacrolimus, and nitrogen mustard are used infrequently. Phototherapy utilizes ultraviolet radiation (UVA and UVB) and is considered an effective treatment for early-stage (IA and IB) MF and SS. However, it has not been FDA-approved due to a lack of prospective trials. Photodynamic therapy is a form of photochemotherapy utilizing porphyrin induced selective, localized production of cytotoxic oxygen species at the tumor site. Electron beam therapy is localized radiation therapy using electron beams and is known to have a complete remission of up to 80 percent.[43][44][45][46][47][48][49]

Systemic therapy

Systemic agents are used for advanced disease (stage III/IV) and maybe also be used in persistent/relapsed stage I disease. Oral bexarotene is a retinoid used as a first-line systemic agent in MF, with an overall response rate of 45 to 57 percent. It has many adverse effects such as hypertriglyceridemia and central hypothyroidism and should never be used in pregnancy or anticipated pregnancy due to its teratogenic effects. Histone deacetylase inhibitors such as romidepsin and interferon-alpha have been used as monotherapy or combination therapy with other systemic options.[50][46][51][52][53] As monotherapy, their overall response rate ranges between 35 to 50 percent. Extracorporeal photopheresis (ECP) involves the administration of Psoralens, which is a photoactive compound followed by UVA radiation, also known as PUVA. Retrospective reviews have revealed improved survival advantage with ECP.

Alemtuzumab, a humanized monoclonal antibody of CD52, depletes leukemic cells and is highly effective in SS. Brentuximab vedotin, a monoclonal antibody conjugate of CD30, recently showed an overall response rate of 54 percent in MF. Chemotherapy options include alkylating agents (cyclophosphamide, chlorambucil), Antimetabolites (pralatrexate), and anthracyclines (doxorubicin). Treatment with single-agent chemotherapy resulted in a higher incidence of large cell transformation associated with a poor prognosis than the original diagnosis. Combined multimodality therapy was associated with much better outcomes.[54][55][56][57][58][59]

Differential Diagnosis

Angioimmunoblastic T Cell Lymphoma

Given the presentation of type B symptoms, rash, lymphadenopathy, differential diagnoses include cutaneous lymphoid neoplasms (including cutaneous lymphomas), infections, an autoimmune disease. The pathological examination of suspicious lesions clinches the diagnosis. 

Large Cell Cutaneous Ki-1 Anaplastic Lymphoma

Differential diagnosis includes Hodgkin's lymphoma and T-cell lymphomas, in which CD30 can be expressed.

Cutaneous T-cell Lymphoma

Benign dermatoses seem to be the most prominent differential diagnoses for cutaneous T-cell lymphomas. These conditions include psoriasis, contact dermatitis, drug eruption. Several of these benign dermatoses may even have T-cell rearrangements (TCR).

Staging

Angioimmunoblastic T-cell Lymphoma

They are classified according to Lugano classification for non-Hodgkin lymphoma. Divided into four stages: Stage I is a single lymph node region or one extra lymphatic region or site. Stage II is two lymph node regions on the same side of the diaphragm or with localized involvement of an extra lymphatic organ. Stage III refers to lymph node involvement on both sides of the diaphragm. Stage 4 refers to the widespread involvement of one or more extra lymphatic organs (lung, bone marrow).[60]

Cutaneous T Cell Lymphomas

Staging has been discussed above under the management section.

Prognosis

Angioimmunoblastic T Cell Lymphoma

Up to 4 prognostic scoring systems are currently in use for AITL. These include IPI (International prognosis index), mPIT (Modified prognostic index for PTCL), IPTCLP (International peripheral T cell lymphoma project score). The use of Age and performance status as markers is consistent among these scoring systems mentioned above. IPTCLP uses platelet count in addition to above, whereas mPIT uses Ki-67%.[61]

Large Cell Cutaneous Ki-1 Anaplastic Lymphoma

When treated, ALK-positive patients (5-year survival of 70-80%) have a better prognosis than ALK-negative patients (5-year survival of 33% to 49%). Relapses worsen the prognosis.

Mycosis Fungoides and Sezary Syndrome

Prognosis largely depends on the stage of the disease. Transformation to large T-cell lymphoma (CD30+ or CD30-) carries unfavorable prognosis.[62][63]

Complications

The commonest cause of death is an infection in both AITL and CTCLs. It contributes to roughly half of the death in these patients. Septicemia and bacterial pneumonia are the most common etiology. About 10% with advanced MF develop herpes virus infection. After infection, widespread visceral involvement seems to be the most frequent cause of death.

Consultations

Peripheral T cell lymphomas are relatively rare hematologic malignancies and need interdisciplinary involvement. This team should comprise a hematologist specializing in lymphomas, hematopathologist, oncologist, primary care physician, oncology nurse, oncological pharmacist, Infectious disease expert, Social worker. Depending on the type of peripheral T cell lymphoma (cutaneous or AITL), this team can also include a dermatologist, radiation oncologist, and palliative medicine specialist.

Deterrence and Patient Education

Patients should be educated about the type of cancer, its prognosis, treatment options, and possible treatment side effects before beginning therapy.

Enhancing Healthcare Team Outcomes

There is no cure for AITL outside the realm of bone marrow transplantation. Early involvement of a hematologist specializing in malignant hematology to choose an ideal chemotherapy regimen to induce remission (either complete or partial remission) in the “transplant eligible” patient is important. In patients who are “transplant-ineligible,” the strategy should be to choose an ideal regimen to increase progression-free survival. A dermatologist, radiation oncologist, and hematologist should evaluate patients with cutaneous T cell lymphomas (MF and PCALCL) to choose an ideal therapeutic regimen that involves a combination of skin directed therapy and systemic therapy or one of them.

A clean line of communication needs to be maintained between these key players mentioned above to provide optimal care to these patients. Treatment of Peripheral T cell lymphomas can result in a lot of drug toxicity; these should be monitored with frequent follow-ups, especially during active chemotherapy.


References

[1] Vose J,Armitage J,Weisenburger D, International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Sep 1;     [PubMed PMID: 18626005]
[2] Savage KJ,Chhanabhai M,Gascoyne RD,Connors JM, Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Annals of oncology : official journal of the European Society for Medical Oncology. 2004 Oct;     [PubMed PMID: 15367405]
[3] Phan A,Veldman R,Lechowicz MJ, T-cell Lymphoma Epidemiology: the Known and Unknown. Current hematologic malignancy reports. 2016 Dec;     [PubMed PMID: 27995419]
[4] Frizzera G,Moran EM,Rappaport H, Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet (London, England). 1974 Jun 1;     [PubMed PMID: 4135245]
[5] Lennert K, [Nature, prognosis and nomenclature of angioimmunoblastic (lymphadenopathy (lymphogranulomatosis X or T-zone lymphoma)]. Deutsche medizinische Wochenschrift (1946). 1979 Aug 31;     [PubMed PMID: 477527]
[6] de Leval L,Rickman DS,Thielen C,Reynies Ad,Huang YL,Delsol G,Lamant L,Leroy K,Brière J,Molina T,Berger F,Gisselbrecht C,Xerri L,Gaulard P, The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007 Jun 1;     [PubMed PMID: 17284527]
[7] Willemze R,Cerroni L,Kempf W,Berti E,Facchetti F,Swerdlow SH,Jaffe ES, The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019 Apr 18;     [PubMed PMID: 30635287]
[8] Laharanne E,Oumouhou N,Bonnet F,Carlotti M,Gentil C,Chevret E,Jouary T,Longy M,Vergier B,Beylot-Barry M,Merlio JP, Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. The Journal of investigative dermatology. 2010 Jun;     [PubMed PMID: 20130593]
[9] Wang SS,Flowers CR,Kadin ME,Chang ET,Hughes AM,Ansell SM,Feldman AL,Lightfoot T,Boffetta P,Melbye M,Lan Q,Sampson JN,Morton LM,Zhang Y,Weisenburger DD, Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. Journal of the National Cancer Institute. Monographs. 2014 Aug;     [PubMed PMID: 25174027]
[10] Ferreira CR,Zhao S,Sanches JA,Miyashiro D,Cury-Martins J,Azevedo RS,Zerbini MCN,Natkunam Y,Gratzinger D, Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil. Diagnostic pathology. 2019 Oct 22     [PubMed PMID: 31640798]
[11] Vose JM, Peripheral T-cell non-Hodgkin's lymphoma. Hematology/oncology clinics of North America. 2008 Oct;     [PubMed PMID: 18954748]
[12] Lunning MA,Vose JM, Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017 Mar 2;     [PubMed PMID: 28115369]
[13] Korgavkar K,Xiong M,Weinstock M, Changing incidence trends of cutaneous T-cell lymphoma. JAMA dermatology. 2013 Nov;     [PubMed PMID: 24005876]
[14] Bradford PT,Devesa SS,Anderson WF,Toro JR, Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009 May 21;     [PubMed PMID: 19279331]
[15] Pomerantz RG,Campbell LS,Jukic DM,Geskin LJ, Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. Archives of dermatology. 2010 May;     [PubMed PMID: 20479299]
[16] Wilkins K,Turner R,Dolev JC,LeBoit PE,Berger TG,Maurer TA, Cutaneous malignancy and human immunodeficiency virus disease. Journal of the American Academy of Dermatology. 2006 Feb;     [PubMed PMID: 16443048]
[17] Burg G,Kempf W,Cozzio A,Feit J,Willemze R,S Jaffe E,Dummer R,Berti E,Cerroni L,Chimenti S,Diaz-Perez JL,Grange F,Harris NL,Kazakov DV,Kerl H,Kurrer M,Knobler R,Meijer CJ,Pimpinelli N,Ralfkiaer E,Russell-Jones R,Sander C,Santucci M,Sterry W,Swerdlow SH,Vermeer MH,Wechsler J,Whittaker S, WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. Journal of cutaneous pathology. 2005 Nov;     [PubMed PMID: 16293178]
[18] Scarisbrick JJ,Kim YH,Whittaker SJ,Wood GS,Vermeer MH,Prince HM,Quaglino P, Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? The British journal of dermatology. 2014 Jun;     [PubMed PMID: 24641480]
[19] Wilson LD,Hinds GA,Yu JB, Age, race, sex, stage, and incidence of cutaneous lymphoma. Clinical lymphoma, myeloma     [PubMed PMID: 23040434]
[20] Sun G,Berthelot C,Li Y,Glass DA 2nd,George D,Pandya A,Kurzrock R,Duvic M, Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. Journal of the American Academy of Dermatology. 2009 Feb;     [PubMed PMID: 19026464]
[21] Criscione VD,Weinstock MA, Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Archives of dermatology. 2007 Jul;     [PubMed PMID: 17638728]
[22] Willemze R,Jaffe ES,Burg G,Cerroni L,Berti E,Swerdlow SH,Ralfkiaer E,Chimenti S,Diaz-Perez JL,Duncan LM,Grange F,Harris NL,Kempf W,Kerl H,Kurrer M,Knobler R,Pimpinelli N,Sander C,Santucci M,Sterry W,Vermeer MH,Wechsler J,Whittaker S,Meijer CJ, WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May 15;     [PubMed PMID: 15692063]
[23] Bekkenk MW,Geelen FA,van Voorst Vader PC,Heule F,Geerts ML,van Vloten WA,Meijer CJ,Willemze R, Primary and secondary cutaneous CD30( ) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000 Jun 15;     [PubMed PMID: 10845893]
[24] Frizzera G,Moran EM,Rappaport H, Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. The American journal of medicine. 1975 Dec;     [PubMed PMID: 1190254]
[25] Federico M,Rudiger T,Bellei M,Nathwani BN,Luminari S,Coiffier B,Harris NL,Jaffe ES,Pileri SA,Savage KJ,Weisenburger DD,Armitage JO,Mounier N,Vose JM, Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jan 10;     [PubMed PMID: 22869878]
[26] Siegert W,Nerl C,Agthe A,Engelhard M,Brittinger G,Tiemann M,Lennert K,Huhn D, Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Annals of oncology : official journal of the European Society for Medical Oncology. 1995 Sep;     [PubMed PMID: 8664186]
[27] Girardi M,Heald PW,Wilson LD, The pathogenesis of mycosis fungoides. The New England journal of medicine. 2004 May 6;     [PubMed PMID: 15128898]
[28] Talpur R,Singh L,Daulat S,Liu P,Seyfer S,Trynosky T,Wei W,Duvic M, Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Sep 15;     [PubMed PMID: 22850569]
[29] Vinuesa CG,Tangye SG,Moser B,Mackay CR, Follicular B helper T cells in antibody responses and autoimmunity. Nature reviews. Immunology. 2005 Nov;     [PubMed PMID: 16261173]
[30] Attygalle A,Al-Jehani R,Diss TC,Munson P,Liu H,Du MQ,Isaacson PG,Dogan A, Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002 Jan 15;     [PubMed PMID: 11781247]
[31] Sabattini E,Pizzi M,Tabanelli V,Baldin P,Sacchetti CS,Agostinelli C,Zinzani PL,Pileri SA, CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013 Aug;     [PubMed PMID: 23716537]
[32] Dupuis J,Boye K,Martin N,Copie-Bergman C,Plonquet A,Fabiani B,Baglin AC,Haioun C,Delfau-Larue MH,Gaulard P, Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. The American journal of surgical pathology. 2006 Apr;     [PubMed PMID: 16625095]
[33] Nelson M,Horsman DE,Weisenburger DD,Gascoyne RD,Dave BJ,Loberiza FR,Ludkovski O,Savage KJ,Armitage JO,Sanger WG, Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. British journal of haematology. 2008 May;     [PubMed PMID: 18341637]
[34] Kerl K,Vonlanthen R,Nagy M,Bolzonello NJ,Gindre P,Hurwitz N,Gudat F,Nador RG,Borisch B, Alterations on the 5' noncoding region of the BCL-6 gene are not correlated with BCL-6 protein expression in T cell non-Hodgkin lymphomas. Laboratory investigation; a journal of technical methods and pathology. 2001 Dec;     [PubMed PMID: 11742039]
[35] Gorczyca W,Tsang P,Liu Z,Wu CD,Dong HY,Goldstein M,Cohen P,Gangi M,Weisberger J, CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis. International journal of oncology. 2003 Feb;     [PubMed PMID: 12527929]
[36] Pimpinelli N,Olsen EA,Santucci M,Vonderheid E,Haeffner AC,Stevens S,Burg G,Cerroni L,Dreno B,Glusac E,Guitart J,Heald PW,Kempf W,Knobler R,Lessin S,Sander C,Smoller BS,Telang G,Whittaker S,Iwatsuki K,Obitz E,Takigawa M,Turner ML,Wood GS, Defining early mycosis fungoides. Journal of the American Academy of Dermatology. 2005 Dec;     [PubMed PMID: 16310068]
[37] Jones D,Dang NH,Duvic M,Washington LT,Huh YO, Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. American journal of clinical pathology. 2001 Jun;     [PubMed PMID: 11392886]
[38] Reimer P,Rüdiger T,Geissinger E,Weissinger F,Nerl C,Schmitz N,Engert A,Einsele H,Müller-Hermelink HK,Wilhelm M, Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 1;     [PubMed PMID: 19029417]
[39] d'Amore F,Relander T,Lauritzsen GF,Jantunen E,Hagberg H,Anderson H,Holte H,Österborg A,Merup M,Brown P,Kuittinen O,Erlanson M,Østenstad B,Fagerli UM,Gadeberg OV,Sundström C,Delabie J,Ralfkiaer E,Vornanen M,Toldbod HE, Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Sep 1;     [PubMed PMID: 22851556]
[40] Schmitz N,Trümper L,Ziepert M,Nickelsen M,Ho AD,Metzner B,Peter N,Loeffler M,Rosenwald A,Pfreundschuh M, Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 Nov 4;     [PubMed PMID: 20660290]
[41] Horwitz S,O'Connor OA,Pro B,Illidge T,Fanale M,Advani R,Bartlett NL,Christensen JH,Morschhauser F,Domingo-Domenech E,Rossi G,Kim WS,Feldman T,Lennard A,Belada D,Illés Á,Tobinai K,Tsukasaki K,Yeh SP,Shustov A,Hüttmann A,Savage KJ,Yuen S,Iyer S,Zinzani PL,Hua Z,Little M,Rao S,Woolery J,Manley T,Trümper L, Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet (London, England). 2019 Jan 19;     [PubMed PMID: 30522922]
[42] Olsen E,Vonderheid E,Pimpinelli N,Willemze R,Kim Y,Knobler R,Zackheim H,Duvic M,Estrach T,Lamberg S,Wood G,Dummer R,Ranki A,Burg G,Heald P,Pittelkow M,Bernengo MG,Sterry W,Laroche L,Trautinger F,Whittaker S, Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 Sep 15;     [PubMed PMID: 17540844]
[43] Lessin SR,Duvic M,Guitart J,Pandya AG,Strober BE,Olsen EA,Hull CM,Knobler EH,Rook AH,Kim EJ,Naylor MF,Adelson DM,Kimball AB,Wood GS,Sundram U,Wu H,Kim YH, Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA dermatology. 2013 Jan;     [PubMed PMID: 23069814]
[44] Morison WL, In vivo effects of psoralens plus longwave ultraviolet radiation on immunity. National Cancer Institute monograph. 1984 Dec;     [PubMed PMID: 6335739]
[45] Pileri A,Delfino C,Grandi V,Pimpinelli N, Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides. Immunotherapy. 2013 Apr;     [PubMed PMID: 23557425]
[46] Piekarz RL,Frye R,Turner M,Wright JJ,Allen SL,Kirschbaum MH,Zain J,Prince HM,Leonard JP,Geskin LJ,Reeder C,Joske D,Figg WD,Gardner ER,Steinberg SM,Jaffe ES,Stetler-Stevenson M,Lade S,Fojo AT,Bates SE, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Nov 10;     [PubMed PMID: 19826128]
[47] Orenstein A,Haik J,Tamir J,Winkler E,Trau H,Malik Z,Kostenich G, Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2000 Aug;     [PubMed PMID: 10940064]
[48] Geskin L, ECP versus PUVA for the treatment of cutaneous T-cell lymphoma. Skin therapy letter. 2007 Jun;     [PubMed PMID: 17609808]
[49] Jones GW,Kacinski BM,Wilson LD,Willemze R,Spittle M,Hohenberg G,Handl-Zeller L,Trautinger F,Knobler R, Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. Journal of the American Academy of Dermatology. 2002 Sep;     [PubMed PMID: 12196745]
[50] Duvic M,Hymes K,Heald P,Breneman D,Martin AG,Myskowski P,Crowley C,Yocum RC, Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 May 1;     [PubMed PMID: 11331325]
[51] Olsen EA, Interferon in the treatment of cutaneous T-cell lymphoma. Dermatologic therapy. 2003;     [PubMed PMID: 14686974]
[52] Edelson R,Berger C,Gasparro F,Jegasothy B,Heald P,Wintroub B,Vonderheid E,Knobler R,Wolff K,Plewig G, Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. The New England journal of medicine. 1987 Feb 5;     [PubMed PMID: 3543674]
[53] Kennedy GA,Seymour JF,Wolf M,Januszewicz H,Davison J,McCormack C,Ryan G,Prince HM, Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. European journal of haematology. 2003 Oct;     [PubMed PMID: 12950233]
[54] Mehra T,Ikenberg K,Moos RM,Benz R,Nair G,Schanz U,Haralambieva E,Hoetzenecker W,Dummer R,French LE,Guenova E,Cozzio A, Brentuximab as a treatment for CD30 mycosis fungoides and Sézary syndrome. JAMA dermatology. 2015 Jan;     [PubMed PMID: 25317818]
[55] Horwitz SM,Kim YH,Foss F,Zain JM,Myskowski PL,Lechowicz MJ,Fisher DC,Shustov AR,Bartlett NL,Delioukina ML,Koutsoukos T,Saunders ME,O'Connor OA,Duvic M, Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 May 3;     [PubMed PMID: 22394596]
[56] Van Scott EJ,Grekin DA,Kalmanson JD,Vonderheid EC,Barry WE, Frequent low doses of intravenous mechlorethamine for late-stage mycosis fungoides lymphoma. Cancer. 1975 Nov;     [PubMed PMID: 1192353]
[57] Wollina U,Dummer R,Brockmeyer NH,Konrad H,Busch JO,Kaatz M,Knopf B,Koch HJ,Hauschild A, Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003 Sep 1;     [PubMed PMID: 12942567]
[58] Vonderheid EC, Treatment of cutaneous T cell lymphoma: 2001. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 2002;     [PubMed PMID: 12079229]
[59] Vonderheid EC, Treatment planning in cutaneous T-cell lymphoma. Dermatologic therapy. 2003;     [PubMed PMID: 14686969]
[60] Lewis WD,Lilly S,Jones KL, Lymphoma: Diagnosis and Treatment. American family physician. 2020 Jan 1     [PubMed PMID: 31894937]
[61] Gutiérrez-García G,García-Herrera A,Cardesa T,Martínez A,Villamor N,Ghita G,Martínez-Trillos A,Colomo L,Setoain X,Rodríguez S,Giné E,Campo E,López-Guillermo A, Comparison of four prognostic scores in peripheral T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Feb;     [PubMed PMID: 20631009]
[62] Epstein EH Jr,Levin DL,Croft JD Jr,Lutzner MA, Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings. Medicine. 1972 Jan;     [PubMed PMID: 5009530]
[63] Benner MF,Jansen PM,Vermeer MH,Willemze R, Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012 Feb 16;     [PubMed PMID: 22160616]